212 reports of this reaction
1.3% of all BLINATUMOMAB reports
#17 most reported adverse reaction
CONFUSIONAL STATE is the #17 most commonly reported adverse reaction for BLINATUMOMAB, manufactured by Amgen, Inc. There are 212 FDA adverse event reports linking BLINATUMOMAB to CONFUSIONAL STATE. This represents approximately 1.3% of all 16,815 adverse event reports for this drug.
Patients taking BLINATUMOMAB who experience confusional state should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONFUSIONAL STATE is a less commonly reported adverse event for BLINATUMOMAB, but still significant enough to appear in the safety profile.
In addition to confusional state, the following adverse reactions have been reported for BLINATUMOMAB:
The following drugs have also been linked to confusional state in FDA adverse event reports:
CONFUSIONAL STATE has been reported as an adverse event in 212 FDA reports for BLINATUMOMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONFUSIONAL STATE accounts for approximately 1.3% of all adverse event reports for BLINATUMOMAB, making it a notable side effect.
If you experience confusional state while taking BLINATUMOMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.